Table 1. Patient clinical and demographic characteristics.
Table 2. Pharmacy refill patterns for adalimumab and etanercept.
Figure 1. Pharmacy refill patterns for adalimumab and etanercept during the first year of treatment.
Table 3. Time intervals between infliximab infusions (n = 457).
Table 4. Annual cumulative anti-TNF cost considerations using doses within the United States FDA-approved prescribing information (first year of persistent treatment).
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
